Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
- Imugene HER-Vaxx Clinical Trial Collaboration with Merck
- Oncolytic Virotherapy CF33 Patent Granted in Japan
- PD1-Vaxx Clinical Trial Supply Agreement with Roche
- HER-Vaxx Immunotherapy Patent Granted in Europe
Later from Imugene
- Termination of Supply Agreement
- Clarification Announcement
- IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
- Imugene doses first patient in VAXINIA Phase 1 trial
- Final HER-Vaxx Phase 2 Trial Overall Survival Results
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene